Ocrevus 300 MG/10 ML vial 10ML
Ended Awarded
- Contract number
- SPE2DR26FU2GV
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,638
Award facts
- Contract value 100% obligated
- $25,637.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $25,637.70 delivery order to Amerisourcebergen Drug Corp on July 23, 2026, for Ocrevus (ocrelizumab) 300 mg/10 ml vial supply. Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of August 13, 2026. No set-aside was used.
Quick answers
Who was awarded contract SPE2DR26FU2GV?
SPE2DR26FU2GV was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on July 23, 2026.
How much is contract SPE2DR26FU2GV worth?
The government has obligated $25,638 on SPE2DR26FU2GV.
Is contract SPE2DR26FU2GV an order under another contract?
Yes. SPE2DR26FU2GV is a delivery order under SPE2DR25D3201, an indefinite delivery contract.
Was contract SPE2DR26FU2GV competed?
The extent of competition for SPE2DR26FU2GV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award